Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer’s Disease



Summary



GBI Research’s report “Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer’s Disease” provides in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan. The revenue and annual cost of therapy are forecast for the key geographies and in seven key therapeutic segments, along with epidemiology data, until 2019. The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barré Syndrome (GBS), Myasthenia Gravis (MG), Idiopathic Thrombocytopenic Purpura (ITP), and Chronic Lymphocytic Leukemia (CLL). The report also profiles the marketed products, key pipeline products, and leading companies that could change the market landscape in the forecast period.

The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research expects the immunoglobulin market to see a slight increase in its growth rate during the 2012–2019 forecast period. It was worth $3.6 billion in 2012, having grown at a Compound Annual Growth Rate (CAGR) of 6% from 2006. Demand for immunoglobulin products continues to increase due to growing disease awareness and therapeutic usage in a wide range of therapeutic areas. Immunology and neurology are the disciplines that use the most immunoglobulins, while PI and CIDP are the top indications. Geographically, the US is the largest market, commanding a share of over 70% of the global market. 11 new products have been approved in the US since 2006, but as many are for PI or ITP, immunoglobulin usage in the US remains off-label for all other indications.

Baxter, CSL Behring, and Grifols continue to command the top ranks in terms of revenue, and recent approvals of Subcutaneous Immunoglobulins (SCIGs) in the US and Europe will further boost market growth.



Scope


- Annualized market data for the immunoglobulin market from 2006 to 2012 and forecast to 2019
- Analysis of the seven key therapeutic segments: PI, CIDP, MMN, MG, CLL, GBS and ITP
- Analysis of the immunoglobulins markets in the leading global geographies: the US, the top five European countries, and Japan
- Market characterization of the immunoglobulin market, covering size, revenue analysis by geography, annual cost of therapy, and epidemiology
- Key drivers and barriers that have a significant impact on the market
- Coverage of key marketed products, approved indications, and safety and efficacy profiles
- Coverage of the pipeline molecules in various phases of drug development
- Competitive profiling of the leading companies: Baxter, Biotest, Bio Products Laboratory, CSL Behring, Grifols, and Octapharma
- Key M&A activity and licensing agreements between 2012 and mid-2013 in the global immunoglobulin market
- Overview of the immunoglobulin markets in Asia-Pacific and China, covering regulations, key players and marketed products



Reasons to buy


- Align your product portfolio to the markets with high growth potential
- Develop market-entry and market-expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
- Develop key strategic initiatives by understanding the key focus areas of the leading companies
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Table Of Contents

Table of Contents

1 Table of CContents 5
1.1 List of Tables 8
1.2 List of Figures 11
2 Immunoglobulins Market to 2019 - Introduction 12
2.1 Overview 12
3 Immunoglobulins Market to 2019 - Market Overview 13
3.1 Revenue 13
3.2 Annual Cost of Therapy 14
3.3 Immunoglobulins Market Drivers and Restraints 15
3.3.1 Market Drivers 15
3.3.2 Restraints 16
4 Immunoglobulins Market to 2019 - Geographical Landscape 17
4.1 US 17
4.1.1 Revenue 17
4.1.2 Annual Cost of Therapy 19
4.2 Top Five European Countries 20
4.2.1 Revenue 20
4.2.2 Annual Cost of Therapy 22
4.3 Japan 23
4.3.1 Revenue 23
4.3.2 Annual Cost of Therapy 24
5 Immunoglobulins Market to 2019 - Therapeutic Landscape 25
5.1 Main Therapeutic Indications 25
5.1.1 Indicated Conditions for Intravenous Immunoglobulin Usage - US 25
5.1.2 Indications for Intravenous Immunoglobulin Usage - Europe 25
5.1.3 Guidelines for Intravenous Immunoglobulin Usage - UK 26
5.1.4 Indications for Intravenous Immunoglobulin Usage - Japan 26
5.2 Revenue Share for the Major Therapeutic Indications 27
5.3 Primary Immunodeficiency Market 28
5.3.1 Introduction 28
5.3.2 Revenue 29
5.3.3 Annual Cost of Therapy 31
5.3.4 Epidemiology 33
5.3.5 Current Use 35
5.3.6 Geographical Segmentation 36
5.4 Guillain-Barre Syndrome Market 37
5.4.1 Introduction 37
5.4.2 Revenue 38
5.4.3 Annual Cost of Therapy 39
5.4.4 Epidemiology 40
5.4.5 Current Use for Therapies 41
5.4.6 Geographical Segmentation 42
5.5 Chronic Lymphocytic Leukemia Market 44
5.5.1 Introduction 44
5.5.2 Revenue 45
5.5.3 Annual Cost of Therapy 46
5.5.4 Epidemiology 47
5.5.5 Current Use 48
5.5.6 Geographical Segmentation 49
5.6 Chronic Inflammatory Demyelinating Polyneuropathy Market 51
5.6.1 Introduction 51
5.6.2 Revenue 52
5.6.3 Annual Cost of Therapy 53
5.6.4 Epidemiology 54
5.6.5 Current Use 55
5.6.6 Geographical Segmentation 56
5.7 Myasthenia Gravis Market 58
5.7.1 Introduction 58
5.7.2 Revenue 59
5.7.3 Annual Cost of Therapy 60
5.7.4 Epidemiology 61
5.7.5 Current Use 62
5.7.6 Geographical Segmentation 63
5.8 Multifocal Motor Neuropathy Market 65
5.8.1 Introduction 65
5.8.2 Revenue 66
5.8.3 Annual Cost of Therapy 67
5.8.4 Epidemiology 68
5.8.5 Current Use 69
5.8.6 Geographical Segmentation 70
5.9 Idiopathic Thrombocytopenic Purpura 72
5.9.1 Introduction 72
5.9.2 Revenue 73
5.9.3 Annual Cost of Therapy 74
5.9.4 Epidemiology 75
5.9.5 Current Use 76
5.9.6 Geographical Segmentation 77
6 Immunoglobulins Market to 2019 - Profiles of Marketed Products 79
6.1 Overview 79
6.2 Privigen 81
6.2.1 Overview 81
6.2.2 Approved Indications 81
6.2.3 Safety 81
6.2.4 Efficacy 82
6.3 Gammagard S/D 83
6.3.1 Overview 83
6.3.2 Approved Indications 83
6.3.3 Safety 83
6.3.4 Efficacy 84
6.4 Gammagard Liquid 85
6.4.1 Overview 85
6.4.2 Approved Indications 85
6.4.3 Safety 85
6.4.4 Efficacy 86
6.5 Octagam 5% 87
6.5.1 Overview 87
6.5.2 Approved Indications 87
6.5.3 Safety 87
6.5.4 Efficacy 88
6.6 Flebogamma 10% DIF 88
6.6.1 Overview 88
6.6.2 Approved Indications 88
6.6.3 Safety 88
6.6.4 Efficacy 88
6.7 Gamunex-C 89
6.7.1 Overview 89
6.7.2 Approved Indications 89
6.7.3 Safety 89
6.7.4 Efficacy 90
6.8 Gammaplex 91
6.8.1 Overview 91
6.8.2 Approved Indications 91
6.8.3 Safety 91
6.8.4 Efficacy 92
6.9 HyQvia 93
6.9.1 Overview 93
6.9.2 Approved Indications 93
6.9.3 Safety 93
6.9.4 Efficacy 93
6.10 Bivigam 94
6.10.1 Overview 94
6.10.2 Approved Indications 94
6.10.3 Safety 94
6.10.4 Efficacy 94
7 Immunoglobulins Market to 2019 - Pipeline Analysis 95
7.1 Research and Development Pipeline 95
7.2 Major Pipeline Product Profiles 97
7.2.1 IVIG3I Grifols 10% 97
7.2.2 RI-002 (IVIG) 98
8 Immunoglobulins Market to 2019 - Competitive Landscape 99
8.1 Baxter International Inc. 99
8.1.1 Business Description 99
8.1.2 Recent Developments 100
8.2 Biotest Pharmaceuticals 101
8.2.1 Business Description 101
8.2.2 Recent Developments 101
8.3 Bio Products Laboratory Ltd. 102
8.3.1 Business Description 102
8.3.2 Recent Developments 102
8.4 CSL Behring Limited 103
8.4.1 Business Description 103
8.4.2 Recent Developments 103
8.5 Grifols S.A. 104
8.5.1 Business Description 104
8.5.2 Recent Developments 105
8.6 Octapharma AG 106
8.6.1 Business Description 106
8.6.2 Recent Developments 106
9 Immunoglobulins Market to 2019 - MandA and Licensing Deals Landscape 107
9.1 MandA Deals 107
9.1.1 Grifols Buys 60% of Progenika Biopharma 107
9.1.2 Grifols Acquires 40% of the Capital of Biotechnology Firm VCN Bioscience 107
9.1.3 Grifols Purchases Three Plasma Donation Centers in the US from Canada’s Cangene 107
9.1.4 Baxter Enhances Renal Therapies Portfolio with Acquisition of Gambro 107
9.2 RandD Licensing Agreements 108
9.2.1 Baxter and Onconova Announce European Licensing Agreement for Anti-Cancer Compound Rigosertib 108
9.2.2 Baxter Announces Collaboration with Sanquin to Expand Capacity for Plasma Therapies 108
9.2.3 Baxter Announces 20 Year Partnership with Hemobras in Brazil 108
10 Immunoglobulins Market to 2019 - Asia-Pacific and China 109
10.1 India 109
10.1.1 Overview 109
10.1.2 Regulatory Landscape 109
10.1.3 National Institute for Biologicals 110
10.1.4 Marketed Products 110
10.1.5 Product Profiles 113
10.1.6 Company Profiling 114
10.2 China 118
10.2.1 Overview 118
10.2.2 Regulatory Information 118
10.2.3 Marketed Products 120
10.2.4 Company Profiling 121
10.3 Australia 123
10.3.1 Overview 123
10.3.2 Regulatory Landscape 125
10.3.3 Marketed Products 126
10.3.4 Product Profiles 127
10.3.5 Company Profiling 128
11 Global Immunoglobulins Market: Appendix 129
11.1 Market Definitions 129
11.2 Abbreviations 129
11.3 References 130
11.4 Research Methodology 132
11.4.1 Coverage 132
11.4.2 Secondary Research 133
11.4.3 Primary Research 133
11.4.4 Expert Panel Validation 133
11.5 Contact Us 134
11.6 Disclaimer 134



List of Tables

Table 1: Immunoglobulins Market, Top Seven Markets, Revenue ($bn), 2006-2012 13
Table 2: Immunoglobulins Market, Top Seven Markets, Revenue Forecast ($bn), 2012-2019 13
Table 3: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy ($), 2006-2012 14
Table 4: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy Forecast ($), 2012-2019 14
Table 5: Immunoglobulins Market, US, Revenue ($bn), 2006-2012 17
Table 6: Immunoglobulins Market, US, Revenue Forecast ($bn), 2012-2019 17
Table 7: Immunoglobulins Market, US, Annual Cost of Therapy ($), 2006-2012 19
Table 8: Immunoglobulins Market, US, Annual Cost of Therapy Forecast ($), 2012-2019 19
Table 9: Immunoglobulins Market, Top Five European Countries, Revenue ($m), 2006-2012 20
Table 10: Immunoglobulins Market, Top Five European Countries, Revenue Forecast ($m), 2012-2019 21
Table 11: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy ($), 2006-2012 22
Table 12: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy Forecast ($), 2012-2019 22
Table 13: Immunoglobulins Market, Japan, Revenue ($m), 2006-2012 23
Table 14: Immunoglobulins Market, Japan, Revenue Forecast ($m), 2012-2019 23
Table 15: Immunoglobulins Market, Japan, Annual Cost of Therapy ($), 2006-2012 24
Table 16: Immunoglobulins Market, Japan, Annual Cost of Therapy Forecast ($), 2012-2019 24
Table 17: Immunoglobulins Market, US, Approved Indications for IVIG Usage, 2012 25
Table 18: Immunoglobulins Market, EU, Indicated Conditions for IVIG Usage, 2012 25
Table 19: Immunoglobulins Market, UK, Guidelines for IVIG Usage, 2012 26
Table 20: Immunoglobulins Market, Top Seven Markets, PI, Revenue ($bn), 2006-2012 29
Table 21: Immunoglobulins Market, Top Seven Markets, PI, Revenue Forecast ($bn), 2012-2019 29
Table 22: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy ($), 2006-2012 31
Table 23: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy Forecast ($), 2012-2019 31
Table 24: Immunoglobulins Market, Top Seven Markets, PI, Epidemiology, 2006-2012 33
Table 25: Immunoglobulins Market, Top Seven Markets, PI, Epidemiology Forecast, 2012-2019 33
Table 26: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue ($m), 2006-2012 36
Table 27: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue Forecast ($m), 2012-2019 36
Table 28: Immunoglobulins Market, Top Seven Markets, GBS, Revenue ($m), 2006-2012 38
Table 29: Immunoglobulins Market, Top Seven Markets, GBS, Revenue Forecast ($m), 2012-2019 38
Table 30: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy ($), 2006-2012 39
Table 31: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy Forecast ($), 2012-2019 39
Table 32: Immunoglobulins Market, Top Seven Markets, GBS, Epidemiology, 2006-2012 40
Table 33: Immunoglobulins Market, Top Seven Markets, GBS, Epidemiology Forecast, 2012-2019 40
Table 34: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue ($m), 2006-2012 42
Table 35: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue Forecast ($m), 2012-2019 43
Table 36: Immunoglobulins Market, Top Seven Markets, CLL, Revenue ($m), 2006-2012 45
Table 37: Immunoglobulins Market, Top Seven Markets, CLL, Revenue Forecast ($m), 2012-2019 45
Table 38: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy ($), 2006-2012 46
Table 39: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy Forecast ($), 2012-2019 46
Table 40: Immunoglobulins Market, Top Seven Markets, CLL, Epidemiology, 2006-2012 47
Table 41: Immunoglobulins Market, Top Seven Markets, CLL, Epidemiology Forecast, 2012-2019 47
Table 42: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue ($m), 2006-2012 49
Table 43: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue Forecast ($m), 2012-2019 50
Table 44: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue ($m), 2006-2012 52
Table 45: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue Forecast ($m), 2012-2019 52
Table 46: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy ($), 2006-2012 53
Table 47: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy Forecast ($), 2012-2019 53
Table 48: Immunoglobulins Market, Top Seven Markets, CIDP, Epidemiology, 2006-2012 54
Table 49: Immunoglobulins Market, Top Seven Markets, CIDP, Epidemiology Forecast, 2012-2019 54
Table 50: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue ($m), 2006-2012 56
Table 51: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue Forecast ($m), 2012-2019 57
Table 52: Immunoglobulins Market, Top Seven Markets, MG, Revenue ($m), 2006-2012 59
Table 53: Immunoglobulins Market, Top Seven Markets, MG, Revenue Forecast ($m), 2012-2019 59
Table 54: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy ($), 2006-2012 60
Table 55: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy Forecast ($), 2012-2019 60
Table 56: Immunoglobulins Market, Top Seven Markets, MG, Epidemiology, 2006-2012 61
Table 57: Immunoglobulins Market, Top Seven Markets, MG, Epidemiology Forecast, 2012-2019 61
Table 58: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue ($m), 2006-2012 63
Table 59: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue Forecast ($m), 2012-2019 64
Table 60: Immunoglobulins Market, Top Seven Markets, MMN, Revenue ($m), 2006-2012 66
Table 61: Immunoglobulins Market, Top Seven Markets, MMN, Revenue Forecast ($m), 2012-2019 66
Table 62: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy ($), 2006-2012 67
Table 63: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy Forecast ($), 2012-2019 67
Table 64: Immunoglobulins Market, Top Seven Markets, MMN, Epidemiology, 2006-2012 68
Table 65: Immunoglobulins Market, Top Seven Markets, MMN, Epidemiology Forecast, 2012-2019 68
Table 66: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue ($m), 2006-2012 70
Table 67: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue Forecast ($m), 2012-2019 71
Table 68: Immunoglobulins Market, Top Seven Markets, ITP, Revenue ($m), 2006-2012 73
Table 69: Immunoglobulins Market, Top Seven Markets, ITP, Revenue Forecast ($m), 2012-2019 73
Table 70: Immunoglobulins Market, Top Seven Markets, ITP, Annual Cost of Therapy ($), 2006-2012 74
Table 71: Immunoglobulins Market, Top Seven Markets, ITP, Annual of Cost Therapy Forecast ($), 2012-2019 74
Table 72: Immunoglobulins Market, Top Seven Markets, ITP, Epidemiology, 2006-2012 75
Table 73: Immunoglobulins Market, Top Seven Markets, ITP, Epidemiology Forecast, 2012-2019 75
Table 74: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue ($m), 2006-2012 77
Table 75: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue Forecast ($m), 2012-2019 78
Table 76: Immunoglobulins Market, US, FDA-Approved IVIG Products by Therapeutic Indication, 1994-2013 80
Table 77: Immunoglobulins Market, Top Five European Countries, EMA-Approved IVIG Products by Therapeutic Indication, 2004-2013 80
Table 78: Immunoglobulins Market, Global, Phase III Pipeline Molecules, 2013 95
Table 79: Immunoglobulins Market, Global, Alzheimer’s Disease, Pipeline Molecules, 2013 96
Table 80: Immunoglobulins Market, Grifols, Global, Marketed Immunoglobulin Products, 2013 104
Table 81: Immunoglobulins Market, India, PI, Marketed Products, 2013 110
Table 82: Immunoglobulins Market, India, GBS, Marketed Products, 2013 111
Table 83: Immunoglobulins Market, India, CLL, Marketed Products, 2013 111
Table 84: Immunoglobulins Market, India, CIDP, Marketed Products, 2013 111
Table 85: Immunoglobulins Market, India, ITP, Marketed Products, 2013 112
Table 86: Immunoglobulins Market, India, Reliance Life Sciences, Key Pipeline Products, 2012-2013 115
Table 87: Immunoglobulins Market, India, Zydus Cadila, Key Marketed Products, 2012-2013 116
Table 88: Immunoglobulins Market, India, Sun Pharmaceuticals, Generic Versions of Key Marketed Products, 2012-2013 117
Table 89: Immunoglobulins Market, China, Blood and Blood Products Industry, 1985-2012 119
Table 90: Immunoglobulins Market, Australia, IVIG Issued to Patients, by Therapeutic Indication, 2011 124
Table 91: Immunoglobulins Market, Australia, Marketed Products, CIDP, 2013 126
Table 92: Immunoglobulins Market, Australia, Marketed Products, CLL, 2013 126
Table 93: Immunoglobulins Market, Australia, Marketed Products, GBS, 2013 126
Table 94: Immunoglobulins Market, Australia, Marketed Products, ITP, 2013 126
Table 95: Immunoglobulins Market, Australia, Marketed Products, PI, 2013 127



List of Figures

Figure 1: Immunoglobulins Market, Top Seven Markets, Revenue Forecast ($bn), 2006-2019 13
Figure 2: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy Forecast ($), 2006-2019 14
Figure 3: Immunoglobulins Market, US, Revenue Forecast ($bn), 2006-2019 17
Figure 4: Immunoglobulins Market, US, Annual Cost of Therapy Forecast ($), 2006-2019 19
Figure 5: Immunoglobulins Market, Top Five European Countries, Revenue Forecast ($m), 2006-2019 20
Figure 6: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy ($), 2006-2019 22
Figure 7: Immunoglobulins Market, Japan, Revenue Forecast ($m), 2006-2019 23
Figure 8: Immunoglobulins Market, Japan, Annual Cost of Therapy ($), 2006-2019 24
Figure 9: Immunoglobulins Market, Top Seven Markets, Market Share by Therapeutic Indication (%), 2012 27
Figure 10: Immunoglobulins Market, Top Seven Markets, PI, Revenue Forecast ($bn), 2006-2019 29
Figure 11: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy Forecast ($), 2006-2019 31
Figure 12: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue Forecast ($m), 2006-2019 36
Figure 13: Immunoglobulins Market, Top Seven Markets, GBS, Revenue Forecast ($m), 2006-2019 38
Figure 14: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy Forecast ($), 2006-2019 39
Figure 15: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue Forecast ($m), 2006-2019 42
Figure 16: Immunoglobulins Market, Top Seven Markets, CLL, Revenue Forecast ($m), 2006-2019 45
Figure 17: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy Forecast ($), 2006-2019 46
Figure 18: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue Forecast ($m), 2006-2019 49
Figure 19: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue Forecast ($m), 2006-2019 52
Figure 20: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy Forecast ($), 2006-2019 53
Figure 21: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue Forecast ($m), 2006-2019 56
Figure 22: Immunoglobulins Market, Top Seven Markets, MG, Revenue Forecast ($m), 2006-2019 59
Figure 23: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy Forecast ($), 2006-2019 60
Figure 24: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue Forecast ($m), 2006-2019 63
Figure 25: Immunoglobulins Market, Top Seven Markets, MMN, Revenue Forecast ($m), 2006-2019 66
Figure 26: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy Forecast ($), 2006-2019 67
Figure 27: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue Forecast ($m), 2006-2019 70
Figure 28: Immunoglobulins Market, Top Seven Markets, ITP, Revenue Forecast ($m), 2006-2019 73
Figure 29: Immunoglobulins Market, Top Seven Markets, ITP, Annual Cost of Therapy Forecast ($), 2006-2019 74
Figure 30: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue Forecast ($m), 2006-2019 77
Figure 31: Immunoglobulins Market, US, FDA-Approved Products by Therapeutic Indication, 2003-2013 79
Figure 32: Immunoglobulins Market, Australia, IVIG Issued (g/1,000 population), 2006-2012 123
Figure 33: Immunoglobulins Market, Australia, IVIG Issued to Patients, by Therapeutic Indication, 2011 124



Companies Mentioned

Baxter International Inc.
Biotest Pharmaceuticals
Bio Products Laboratory Ltd.
CSL Behring Limited
Grifols S.A.
Octapharma AG

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cance ...

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

Global Mobile Healthcare Market Devices, Applications, Services Industry Size, Analysis, Market Report, Share, Growth, Trends and Forecast 2014-20

Global Mobile Healthcare Market Devices, Applications, Services Industry Size, Analysis, Market Report, Share, Growth, Trends and Forecast 2014-20

  • $ 7 000
  • Industry report
  • November 2014
  • by Occams

According to WHO approximately 17.3 million people die annually due to CVD and the condition is responsible for 30 percent of the global deaths. Also, 80 percent of CVD deaths take place in low and middle ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.